{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:18:16Z","timestamp":1793441896770,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Japanese Society for the Promotion of Science","award":["24K13536"],"award-info":[{"award-number":["24K13536"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01613-8","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:52:43Z","timestamp":1791017563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Romosozumab Prescribing in Relation to Cardiovascular Disease History in Japan: A Nationwide Claims Database Study"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-258X","authenticated-orcid":false,"given":"Yuki","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyasu","family":"Kouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nakatoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumito","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"20","key":"1613_CR1","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883\u201319887. https:\/\/doi.org\/10.1074\/jbc.M413274200","journal-title":"J Biol Chem"},{"issue":"5","key":"1613_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"issue":"16","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"1613_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"9","key":"1613_CR5","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"issue":"10102","key":"1613_CR6","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet (London, England) 390(10102):1585\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(17)31613-6","journal-title":"Lancet (London, England)"},{"key":"1613_CR7","unstructured":"U.S. Food and Drug Administration (2019) Evenity: Drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s000lbl.pdf. Accessed 8 August 2026"},{"key":"1613_CR8","unstructured":"European Medicines Agency (2019) Evenity: EPAR\u2014Product Information. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evenity-epar-product-information_en.pdf. Accessed 8 August 2026"},{"key":"1613_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency (2019) Summary of Investigation Results: Romosozumab (genetical recombination) https:\/\/www.pmda.go.jp\/files\/000231403.pdf?utm_source=chatgpt.com. Accessed 8 August 2026"},{"issue":"1","key":"1613_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00223-026-01572-0","volume":"117","author":"Y Fujita","year":"2026","unstructured":"Fujita Y, Kouda K, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S, Ogawa S, Iki M (2026) Cardiovascular safety of romosozumab versus other anti-osteoporosis medications in patients with osteoporosis: a nationwide health insurance claims database study in Japan. Calcif Tissue Int 117(1):110. https:\/\/doi.org\/10.1007\/s00223-026-01572-0","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1613_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00774-024-01530-6","volume":"42","author":"S Soen","year":"2024","unstructured":"Soen S, Wang A, Hamaya E, Chien HC, Lin TC (2024) Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019\u20132021. J Bone Miner Metab 42(6):653\u2013667. https:\/\/doi.org\/10.1007\/s00774-024-01530-6","journal-title":"J Bone Miner Metab"},{"issue":"3\u20134","key":"1613_CR12","first-page":"55","volume":"6","author":"S Matsuda","year":"2012","unstructured":"Matsuda S, Fujimori K (2012) The claim database in Japan. Asian Pac J Dis Manag 6(3\u20134):55\u201359","journal-title":"Asian Pac J Dis Manag"},{"key":"1613_CR13","unstructured":"Japanese Ministry of Health Labour, and Welfare (2016) Proportion of electronic claims in the Japanese health insurance system. Japanese Ministry of Health, Labour, and Welfare. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-12400000-Hokenkyoku\/0000099002.pdf. Accessed 8 August 2026"},{"key":"1613_CR14","unstructured":"Japanese Ministry of Health Labour, and Welfare (2026) NDB open data. Japanese Ministry of Health, Labour, and Welfare. https:\/\/www.mhlw.go.jp\/content\/12400000\/001711793.pdf. Accessed 8 August 2026"},{"issue":"5","key":"1613_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"11","key":"1613_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130\u20131139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care"},{"key":"1613_CR17","unstructured":"Liu Y AT, Curtis J, Zhang J (2023) Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S. Arthritis Rheumatol 75 (Suppl 9)"},{"issue":"1","key":"1613_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/1471-2474-14-276","volume":"14","author":"C-K Chiu","year":"2013","unstructured":"Chiu C-K, Kuo M-C, Yu S-F, Su BY-J, Cheng T-T (2013) Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord 14(1):276. https:\/\/doi.org\/10.1186\/1471-2474-14-276","journal-title":"BMC Musculoskelet Disord"},{"key":"1613_CR19","volume-title":"Guidelines for prevention and treatment of osteoporosis 2025 edition","author":"The Committee for Developing Guidelines for Prevention and Treatment of Osteoporosis","year":"2025","unstructured":"The Committee for Developing Guidelines for Prevention and Treatment of Osteoporosis (2025) Guidelines for prevention and treatment of osteoporosis 2025 edition. Lifescience Publishing, Tokyo"},{"key":"1613_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruy\u00e8re O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporos Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01613-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:17Z","timestamp":1791061337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01613-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01613-8","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nobukazu Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd., and payments for lectures, including speakers\u2019 bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd., Amgen K.K., Daiichi-Sankyo Co., Ltd., and Teijin Pharma Ltd. Sumito Ogawa has received payments for lectures from Tsumura Co., Ltd., and Daiichi-Sankyo Co., Ltd. Masayuki Iki, Yuki Fujita, Katsuyasu Kouda, Kenji Fujimori, Shinichi Nakatoh, Shigeyuki Ishii, and Junko Tamaki declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the MHLW (Approval No. Ho0713-5-1498; 13 July 2023), the Ethics Committee of Osaka Medical and Pharmaceutical University (Approval No. 2023\u2013028; 22 May 2023 revised on 9 December 2025), and the Ethics Committee of Kansai Medical University (Approval No. 2025315; 2 February 2026).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We analyzed data provided by the MHLW which were completely anonymous. Therefore, informed consent from each patient was not required.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Publication of the present manuscript was approved by the MHLW (No. 2026-106; 16 June 2026) and all authors.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"156"}}